UAE-based Gulf & Word Traders (GTW), a leading medical equipment provider, has partnered with US-based Everist Genomics to offer a new non-invasive test that predicts risk for cardiovascular disease.

Everist Genomics, developer of the test, has announced that it has appointed Gulf & World Traders as exclusive agents of the technology in the region.

"We are delighted to be partnering with a well-established and respected organization that has the capacity to serve the market and make our breakthrough technology widely available," said Everist Genomics CEO, Steve Everist.

"Cardiovascular disease is a major life threat in the Gulf region as it is in many other countries of the world, and we believe that this new heart health predictor will be a valuable asset in identifying people who are at risk so that they, together with their physicians, can take the appropriate measures to lower their risk of heart attack or stroke," said Nabil Emil, general manager, Gulf & World Traders.

The medical device, known as AngioDefender, determines vascular health status by measuring the ability of patient's arteries to naturally expand in response to changes within the body, known as endothelial function.

Endothelial function is a known indicator of atherosclerosis and coronary heart disease and has also been linked to risk for dementia.  Previously, the only reliable methods for testing proper endothelial function requires special equipment and training to perform and are not readily available.

AngioDefender's  patented technology solves this problem with a simple, reliable and fast test that is remarkably easy to administer.   Using the device, patients will know immediately if they are at low, medium or high risk for cardiovascular disease.

"The beauty of this test is that it can identify those who are at risk for cardiovascular disease even though they may currently have no obvious symptoms such as high blood pressure or poor cholesterol levels," added Everist. – TradeArabia News Service